Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
2.60
Dollar change
+0.11
Percentage change
4.42
%
IndexRUT P/E- EPS (ttm)-0.44 Insider Own25.34% Shs Outstand169.87M Perf Week1.96%
Market Cap466.67M Forward P/E- EPS next Y-0.53 Insider Trans-0.07% Shs Float134.01M Perf Month-10.96%
Income-72.85M PEG- EPS next Q-0.11 Inst Own43.84% Short Float3.08% Perf Quarter8.79%
Sales18.14M P/S25.73 EPS this Y-1.82% Inst Trans4.56% Short Ratio4.32 Perf Half Y34.02%
Book/sh0.62 P/B4.17 EPS next Y-18.30% ROA-42.88% Short Interest4.13M Perf Year-15.03%
Cash/sh0.70 P/C3.70 EPS next 5Y- ROE-59.99% 52W Range1.69 - 3.14 Perf YTD4.00%
Dividend Est.- P/FCF- EPS past 5Y18.41% ROI-63.73% 52W High-17.33% Beta2.03
Dividend TTM- Quick Ratio5.87 Sales past 5Y55.33% Gross Margin92.26% 52W Low53.85% ATR (14)0.09
Dividend Ex-Date- Current Ratio5.87 EPS Y/Y TTM4.63% Oper. Margin-430.15% RSI (14)47.90 Volatility2.89% 3.36%
Employees73 Debt/Eq0.08 Sales Y/Y TTM-53.51% Profit Margin-401.57% Recom1.40 Target Price4.40
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q19.23% Payout- Rel Volume0.87 Prev Close2.49
Sales Surprise-55.25% EPS Surprise-3.45% Sales Q/Q-65.65% EarningsFeb 29 BMO Avg Volume956.30K Price2.60
SMA20-1.85% SMA50-0.57% SMA20017.10% Trades Volume830,398 Change4.42%
Date Action Analyst Rating Change Price Target Change
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Mar-08-24 07:30AM
Mar-01-24 08:17AM
Feb-29-24 11:14PM
08:40AM
07:52AM
07:30AM Loading…
07:30AM
Feb-15-24 07:30AM
Jan-08-24 07:30AM
Nov-09-23 04:24PM
04:01PM
09:12AM
Nov-08-23 07:30AM
01:16AM
Nov-07-23 08:05AM
07:40AM
07:30AM Loading…
07:30AM
07:15AM
Oct-30-23 09:32AM
Oct-24-23 07:30AM
Oct-18-23 07:30AM
Oct-11-23 08:05AM
Sep-12-23 10:56AM
08:58AM
Sep-11-23 04:15PM
Sep-07-23 07:30AM
Aug-04-23 03:29PM
Aug-03-23 08:55AM
07:49AM
07:30AM
Jul-23-23 10:19AM
07:30AM Loading…
Jul-20-23 07:30AM
Jul-12-23 07:30AM
Jul-10-23 04:01PM
Jun-23-23 09:40AM
Jun-21-23 07:30AM
02:01AM
Jun-07-23 09:40AM
02:01AM
Jun-01-23 11:29AM
May-31-23 07:30AM
May-30-23 09:26AM
May-29-23 10:08AM
May-22-23 09:40AM
May-17-23 07:38AM
May-09-23 12:00PM
07:30AM
May-04-23 11:52PM
09:40AM
08:55AM
07:30AM
Apr-27-23 03:20AM
Apr-25-23 11:57AM
11:50AM
07:30AM
Apr-20-23 07:30AM
Apr-18-23 04:01PM
02:18PM
Apr-12-23 12:37PM
Apr-11-23 03:30PM
01:00PM
Apr-04-23 04:08PM
08:22AM
08:17AM
07:52AM
Mar-24-23 12:29PM
Mar-19-23 10:17AM
Mar-16-23 07:30AM
Mar-14-23 04:05PM
Mar-10-23 06:36PM
Mar-06-23 01:55AM
Mar-03-23 03:50AM
Mar-02-23 09:25AM
07:30AM
Feb-16-23 07:30AM
Feb-15-23 12:02PM
Feb-13-23 07:01AM
Feb-06-23 07:30AM
Jan-27-23 07:30AM
Jan-11-23 10:24PM
Jan-05-23 07:30AM
Dec-13-22 07:30AM
Dec-08-22 06:34AM
Nov-11-22 05:20AM
Nov-09-22 08:45AM
07:30AM
Nov-08-22 07:30AM
Nov-01-22 04:01PM
Oct-31-22 04:02PM
Oct-26-22 07:30AM
Oct-09-22 10:05AM
Sep-30-22 09:00AM
Sep-22-22 07:30AM
Sep-06-22 07:30AM
06:54AM
Sep-01-22 12:38PM
Aug-30-22 07:30AM
Aug-26-22 09:41AM
Aug-10-22 06:26AM
Aug-04-22 07:30PM
09:05AM
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McElhaugh Michael J.Interim President & CEOFeb 02 '24Sale2.3110,16423,5041,504,793Feb 05 07:54 PM
Sofia Michael J.Chief Scientific OfficerFeb 02 '24Sale2.319,98223,0831,485,121Feb 05 07:54 PM
HASTINGS DAVID CChief Financial OfficerFeb 02 '24Sale2.319,59322,184181,907Feb 05 07:54 PM
Sims KarenChief Medical OfficerFeb 02 '24Sale2.314,35810,078125,542Feb 05 07:55 PM